New scorpion venom peptide blocks Kv1.3 potassium channels linked to autoimmune diseases | Research

The takeaway

Meuk7-3, a peptide from scorpion venom, blocks Kv1.3 channels through Lys19 interaction with pore tyrosines, and computationally designed analogs show improved binding affinity and drug-like properties for potential autoimmune disease treatment.

Improved analog designed
Computational redesign of scorpion venom peptide Meuk7-3 yielded Meuk7-3A with better Kv1.3 binding and drug-like properties for autoimmune disease targeting

What the researchers found

Meuk7-3 blocks Kv1.3 via Lys19 interaction with Tyr447/797/1147/1497 in the channel pore. Three designed analogs showed improved binding stability and affinity. Meuk7-3A had the best drug-like properties and Kv1.3 binding among all tested peptides.

Why it matters

Kv1.3 channels on immune cells drive autoimmune inflammation. Highly selective blockers could treat diseases like MS and RA by suppressing pathogenic immune cells while sparing normal immunity—a precision approach that current immunosuppressants lack.

How the study worked

Peptide characterization from scorpion venom, molecular docking, molecular dynamics simulations, binding affinity analysis, and computational drug-likeness assessment of native and designed analogs.

What this study cannot tell us

Entirely computational after initial peptide identification. No experimental electrophysiology or cell-based validation. Designed analogs need synthesis and in vitro/in vivo testing. Selectivity over other Kv channels not experimentally confirmed.

How to read the evidence

Computational study with in silico validation only. Provides strong theoretical rationale but requires experimental confirmation of binding, selectivity, and therapeutic efficacy.

When this study was published

Published in 2025; contributes to the growing field of venom-derived peptide therapeutics.

The bigger picture

Venomous animals are a rich source of ion channel-targeting peptides. This study demonstrates how natural venom peptides can be computationally optimized for therapeutic use, combining the selectivity of evolution-refined toxins with modern drug design.

Questions still open

Will Meuk7-3A show selective Kv1.3 blockade without affecting Kv1.1 or Kv1.2 in electrophysiology studies?
Can these peptides be synthesized at scale and retain activity?
How do they compare to existing Kv1.3 blockers like ShK-186 in preclinical models?

Common questions

Why study scorpion venom for medicine?

Scorpion venom contains highly specific peptide toxins that target ion channels with precision refined by millions of years of evolution. Kv1.3-blocking peptides from scorpions can selectively suppress the immune cells responsible for autoimmune diseases without broadly suppressing the entire immune system.

What diseases could Kv1.3 blockers treat?

Kv1.3 channels are found at high levels on the immune cells that drive autoimmune diseases like multiple sclerosis, rheumatoid arthritis, and type 1 diabetes. Blocking these channels can calm down overactive immune responses while leaving normal immunity intact.

Read the original research

Unveiling new Kv1.3 channel blockers from scorpion venom: Characterization of Meuk7-3 and in silico design of its analogs for enhanced affinity and therapeutic potential.

International journal of biological macromolecules, 319(Pt 2), 145327

View on PubMed ↗Publisher’s paper ↗

Citation

Shariati, Saeedeh; Mafakher, Ladan; Shirani, Maryam; Baradaran, Masoumeh. (2025). Unveiling new Kv1.3 channel blockers from scorpion venom: Characterization of Meuk7-3 and in silico design of its analogs for enhanced affinity and therapeutic potential.. International journal of biological macromolecules, 319(Pt 2), 145327. https://doi.org/10.1016/j.ijbiomac.2025.145327